BeiGene/BGNE

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX

About BeiGene

BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.

Ticker

BGNE

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

Headquarters

Grand cayman, Cayman Islands

Employees

10,000
Website
www.beigene.com

BeiGene Metrics

BasicAdvanced
$16B
Market cap
-
P/E ratio
-$7.57
EPS
0.60
Beta
-
Dividend rate
$16B
0.6
$229.57
$126.97
4
2.077
1.839
5.923
30.532
-13.50%
-20.87%
-18.48%
5.799
4.24
4.847
77.42%
58.94%
99.67%

What the Analysts think about BeiGene

Analyst Ratings

Majority rating from 23 analysts.
Buy

BeiGene Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-33.40% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$752M
18.47%
Net income
-$251M
-31.67%
Profit margin
-33.40%
-42.33%

BeiGene Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 5.28%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$3.64
$2.01
-$3.53
-$2.41
-
Expected
-$2.81
-$3.11
-$3.96
-$2.54
-$2.33
Surprise
29.50%
-164.71%
-10.78%
-5.28%
-

BeiGene News

AllArticlesVideos

BeiGene: Navigating Patent Disputes Towards Profitability (Rating Upgrade)

Seeking Alpha·2 weeks ago

BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024

Business Wire·3 weeks ago

BeiGene and NewBridge Pharmaceuticals FZ LLC Mutually Agree to Conclude BRUKINSA® (Zanubrutinib) Partnership in the Middle East and Africa (MENA) Region

Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractionalADR

Upcoming events

No upcoming events

FAQs

What’s the current market cap for BeiGene stock?

BeiGene (BGNE) has a market cap of $16B as of July 03, 2024.

What is the P/E ratio for BeiGene stock?

The price to earnings (P/E) ratio for BeiGene (BGNE) stock is 0 as of July 03, 2024.

Does BeiGene stock pay dividends?

No, BeiGene (BGNE) stock does not pay dividends to its shareholders as of July 03, 2024.

When is the next BeiGene dividend payment date?

BeiGene (BGNE) stock does not pay dividends to its shareholders.

What is the beta indicator for BeiGene?

BeiGene (BGNE) has a beta rating of 0.6. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell BeiGene stock

Buy or sell BeiGene stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing